Atossa Therapeutics Announces npj Breast Cancer Publication Highlighting Novel Endoxifen-Based Compounds In ESR1-Mutant Breast Cancer Models
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant modelsFindings suggest potential for combination with abemaciclibSEATTLE, July 28, 2026
Scientists published a study showing that Atossa's new experimental medicines might work against certain hard-to-treat breast cancers. This is early research, so it's one step forward in a long process—watch to see if the company can actually test these medicines in patients next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.